Skip to main content
    P

    Pacific Biosciences of California (PACB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.82
    -0.02 (-1.09%)

    Market Cap: $574.52M

    Last updated: Nov 17, 2026 at 4:42 PM ET

    Pacific Biosciences of California (PACB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pacific Biosciences of California (PACB) has a market cap of $574.52M and an enterprise value of $1.16B. It kept -81.31% of revenue as net income over the last 12 months. Its net debt of $587.15M equals 102.20% of its market cap.

    Total Valuation

    Enterprise value is 102.20% above the market cap, as debt exceeds cash.

    Market Cap$574.52M
    Enterprise Value$1.16B
    Latest price (Nov 17, 2026)$1.82

    Key Dates

    The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 9, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.19% in the quarter ended Sep 30, 2026 and grew 6.79% a year over 2 years.

    Shares Outstanding311.25M
    Shares Change (YoY)+3.46%
    Shares Change (QoQ)+0.19%
    Share Count Growth (2Y CAGR)+6.79%

    Valuation Ratios

    The price to sales ratio is 3.5x. Its year-end P/S ranged from 3.0x to 56.4x from 2016 to 2025.

    P/S Ratio3.5x
    Forward P/S3.6x

    Price Statistics

    The stock is up 13.04% over 52 weeks and trades 9.90% below its 50-day average.

    Beta (1Y)2.14
    52-Week Change+13.04%
    1-Month Change-1.09%
    3-Month Change+43.31%
    6-Month Change+58.26%
    5-Year Change-90.16%
    10-Year Change-69.35%
    Total Return (1Y)+13.04%
    Total Return (3Y CAGR)-39.93%
    Total Return (5Y CAGR)-40.89%
    Return vs SPY (1Y)-1.26%
    Max Drawdown (1Y)-58.43%
    Max Drawdown (3Y)-91.21%
    Sharpe Ratio (1Y)0.11
    Correlation with SPY (1Y)0.32
    50-Day Average$2.02
    200-Day Average$1.60
    52-Week Range$1.07 to $3.44
    RSI (14 Days)39.8
    Average Volume (20 Days)13.02M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.62x current liabilities.

    Current Ratio4.62x
    Quick Ratio3.72x
    Interest Coverage-16.07x

    Returns and Efficiency

    Return on invested capital is -21.12% over the last 12 months, against a 5-year average of -35.87%.

    Return on Assets (ROA)-18.20%
    Return on Invested Capital (ROIC)-21.12%
    Return on Capital Employed (ROCE)-18.77%
    ROA (5Y Average)-27.73%
    ROIC (5Y Average)-35.87%
    Asset Turnover0.21x
    Inventory Turnover1.74x
    Receivables Turnover4.65x
    Cash Conversion Cycle236 days

    Scores

    PACB has an Altman Z-Score of -4.91, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-4.91
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $161.39M over the last 12 months is up 4.41% from the 12 months before.

    Revenue$161.39M
    Revenue Growth (YoY)+4.41%
    Gross Profit$55.52M
    Operating Income-$131.17M
    Pretax Income-$130.52M
    Net Income-$131.23M
    EBITDA-$105.33M
    EBIT-$122.87M
    Reported EPS (TTM)-$0.49

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$55.91M
    Total Debt$643.06M
    Net Debt$587.15M
    Net Debt Per Share$1.89
    Working Capital$241.26M
    Shareholder Equity-$61.38M
    Tangible Book Value-$391.31M
    Total Assets$721.10M
    Total Liabilities$782.48M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $6.45M of capital spending, operating cash flow left -$143.40M of free cash flow.

    Operating Cash Flow-$136.95M
    Capital Expenditures$6.45M
    Free Cash Flow-$143.40M
    FCF Per Share-$0.46
    Depreciation and Amortization$17.54M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -81.27%.

    Gross Margin34.40%
    Operating Margin-81.27%
    Pretax Margin-80.87%
    Net Margin-81.31%
    EBITDA Margin-65.26%
    EBIT Margin-76.13%
    FCF Margin-88.85%
    Gross Margin (5Y Average)32.49%

    Growth

    Revenue grew 7.64% a year over 3 years.

    Revenue Growth (3Y CAGR)+7.64%
    Revenue Growth (5Y CAGR)+15.19%
    Book Value Per Share Growth (2Y CAGR)-91.79%

    Revenue and profit by year

    Dividends and Yields

    PACB does not pay a dividend. Its free cash flow yield is -25.31%.

    FCF Yield-25.31%
    Buyback Yield-0.56%
    Shareholder Yield-0.56%

    Peer Position

    Against 12 similar companies, PACB has the 8th highest P/S.

    P/S Ratio3.5x vs 4.3x median
    ROIC-21.12% vs -17.35% median
    Revenue Growth (Trailing 4 Quarters, YoY)+4.41% vs +14.20% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 5.50% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+5.50%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PACB

    What is PACB's market cap?

    Pacific Biosciences of California has a market cap of $574.52M. Its enterprise value, which adds debt and subtracts cash, is $1.16B.

    How many shares of PACB are outstanding?

    Pacific Biosciences of California has 311.25M shares outstanding. The count is up 3.46% from a year earlier.

    Does PACB pay a dividend?

    No. Pacific Biosciences of California does not pay a dividend.

    How much debt does PACB have?

    Pacific Biosciences of California has $643.06M of total debt and $55.91M of cash and equivalents, a net debt position of $587.15M.